Maternal SSRI use during pregnancy may be associated with altered brain development in children; however, this study cannot fully rule out contributions of confounding genetic and enviromental factors.
This study provides reassuring data on the use of mirtazapine during pregnancy, demonstrating no association between exposure and risk of major malformations or pregnancy loss.
Consistent with other studies, including a large meta-analysis, this study indicates no increased risk of ADHD in offspring following prenatal exposure to antidepressants.
Analyzing data from nearly 150,000 children with prenatal antidepressant exposure in two healthcare databases, a recent study finds no association between prenatal exposure to antidepressants and risk for neurodevelopmental disorders.
While questions and controversies remain, the information on long-term neurodevelopmental outcomes in children prenatally exposed to antidepressants is largely reassuring.
SSRI and SNRI antidepressants were not associated with an increased risk for gestational diabetes.
In this large study with over 1500 exposures, duloxetine exposure during the first trimester does not appear to increase risk of major malformations.
From the OptumLabs Data Warehouse, researchers identified 226,932 singleton deliveries. Cases of antidepressant exposure were defined as pregnancies with prescription claims for antidepressants submitted between the last menstrual period and 35 weeks’ gestation. To [...]
While we have data to support the use of antidepressants, including the selective serotonin reuptake inhibitors (SSRIs) and the serotonin norepinephrine reuptake inhibitors (SNRIs), during pregnancy, most studies have focused on risk of congenital [...]
Rommel and colleagues present a systematic review examining the long-term effects of prenatal exposure to antidepressants on physical, neurodevelopmental, and psychiatric outcomes in children 4 years of age or older.
